Biotech

MethylGene Reports First Quarter 2013 Financial Results

MONTREAL, CANADA: ...

Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement

SOUTH SAN FRANCISCO, CA and DUBLIN, IRELAND: Theravance to receive $1.0 billion upfront payment upon closing; Elan to receive a 21% participation interest in potential future royalty payments associated with four respiratory programs ...

West Announces Third-Quarter 2013 Dividend

EXTON, PA: ...

Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dependence

TURKU, FINLAND: ...

Triplefin "Connections" Brand Identity Campaign Takes First Place at the DxMA Creative Communications Awards Competition

CINCINNATI, OH: ...

CORRECTION FROM SOURCE/Paladin Labs Reports First Quarter 2013 Results: Achieves Record Revenues

MONTREAL, CANADA: ...

Ceapro Signs a License and Distribution Agreement With Symrise

EDMONTON, ALBERTA: ...

MethylGene Announces Plan to Reincorporate in the United States as Mirati Therapeutics, Inc. and List on the NASDAQ

MONTREAL, CANADA: ...

Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, CA: ...

Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments

CAMBRIDGE, MA: Documents Requested by FDA for Accelerated Approval Consideration of Eteplirsen Will Be Submitted This Month; Clinical, Regulatory, and Manufacturing Activities Continue to Progress for Eteplirsen and ...